Full Press Release Details
MARLBOROUGH, Mass. , April 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated net sales of $4.663 billion during the first quarter of 2025, growing 20.9 percent on a reported basis, 22.2 percent on an operational 1 basis and 18.2 percent on an organic 2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $674 million or $0.45 per share (EPS), compared to $495 million or $0.33 per share a year ago, and achieved adjusted 3 EPS of $0.75 for the period, compared to $0.56 a year ago.
"We delivered an exceptional quarter to start the year, reflecting the effectiveness of our highly engaged global team and the strength of our product portfolio," said Mike Mahoney , chairman and chief executive officer, Boston Scientific. "We remain well-positioned for the future as we continue to focus on meaningful innovation, clinical science and the execution of our category leadership strategy to drive differentiated growth and performance for the long-term."
First quarter financial results and recent developments:
| 1. Operational net sales growth excludes the impact of foreign currency fluctuations. |
| 2. Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. |
| 3. Adjusted EPS excludes the impacts of certain charges (credits) which may include amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio net losses (gains) and impairments, restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits), European Union (EU) Medical Device Regulation (MDR) implementation costs, debt extinguishment net charges, deferred tax expenses (benefits) and certain discrete tax items. |
| 4.Our Emerging Markets countries include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada. |
Net sales for the first quarter by business and region:
| Increase/(Decrease) | |||||||||||||
| Three Months Ended March 31, | Reported Basis | Impact of Foreign Currency Fluctuations | Operational Basis | Impact of Certain Acquisitions/Divestitures | Organic Basis | ||||||||
| (in millions) | 2025 | 2024 | |||||||||||
| Endoscopy | $ 673 | $ 642 | 4.7 % | 1.2 % | 5.9 % | (0.4) % | 5.5 % | ||||||
| Urology | 633 | 513 | 23.5 % | 1.0 % | 24.5 % | (20.1) % | 4.4 % | ||||||
| Neuromodulation | 271 | 256 | 5.8 % | 0.9 % | 6.8 % | — % | 6.8 % | ||||||
| MedSurg | 1,577 | 1,412 | 11.7 % | 1.1 % | 12.8 % | (7.5) % | 5.3 % | ||||||
| Cardiology | 2,429 | 1,872 | 29.8 % | 1.4 % | 31.2 % | — % | 31.2 % | ||||||
| Peripheral Interventions | 656 | 573 | 14.4 % | 1.4 % | 15.8 % | (8.4) % | 7.4 % | ||||||
| Cardiovascular | 3,085 | 2,445 | 26.2 % | 1.4 % | 27.6 % | (2.0) % | 25.6 % | ||||||
| Net Sales | $ 4,663 | $ 3,856 | 20.9 % | 1.3 % | 22.2 % | (4.0) % | 18.2 % |
| Increase/(Decrease) | |||||||||
| Three Months Ended March 31, | Reported Basis | Impact of Foreign Currency Fluctuations | Operational Basis | ||||||
| (in millions) | 2025 | 2024 | |||||||
| U.S. | $ 2,960 | $ 2,258 | 31.1 % | — % | 31.1 % | ||||
| EMEA | 846 | 803 | 5.5 % | 2.4 % | 7.9 % | ||||
| APAC | 701 | 647 | 8.2 % | 2.4 % | 10.6 % | ||||
| LACA | 155 | 149 | 4.4 % | 9.6 % | 14.1 % | ||||
| Net Sales | $ 4,663 | $ 3,856 | 20.9 % | 1.3 % | 22.2 % | ||||
| Emerging Markets 4 | $ 690 | $ 648 | 6.5 % | 3.3 % | 9.8 % | ||||
| Amounts may not add due to rounding. Growth rates are based on actual, non-rounded amounts and may not recalculate precisely. | |||||||||
| Net sales growth rates that exclude the impact of foreign currency fluctuations and/or the impact of certain acquisitions/divestitures are not prepared in accordance with U.S. GAAP. |
Guidance for Full Year and Second Quarter 2025
The company estimates net sales growth for the full year 2025, versus the prior year period, to be approximately 15 to 17 percent on a reported basis and 12 to 14 percent on an organic basis. Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $1.86 to $1.93 and estimates adjusted EPS, excluding certain charges (credits), of $2.87 to $2.94 .
The company estimates net sales growth for the second quarter of 2025, versus the prior year period, to be in a range of approximately 17.5 to 19.5 percent on a reported basis, and 13 to 15 percent on an organic basis. Second quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $0.45 to $0.47 and estimates adjusted EPS, excluding certain charges (credits), of $0.71 to $0.73 .
Conference Call Information Boston Scientific management will be discussing these results with analysts on a conference call today at 8:00 a.m. ET . The company will webcast the call to interested parties through its website: investors.bostonscientific.com . Please see the website for details on how to access the webcast. The webcast will be available for approximately one year on the Boston Scientific website.
About Boston Scientific Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and connect on LinkedIn and X .
Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "may," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our expected net sales; reported, operational and organic revenue growth rates; reported and adjusted EPS for the second quarter and full year 2025; our financial performance; acquisitions; clinical trials; our business plans and product performance; and new and anticipated product approvals and launches. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Note : Amounts reported in millions within this press release are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded amounts.
Use of Non-GAAP Financial Information A reconciliation of the company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company's use of these non-GAAP financial measures, is included in the exhibits attached to this press release.
| CONTACT: | ||||
| Media: | Chanel Hastings | Investors: | Jonathan Monson | |
| 508-382-0288 (office) | 508-683-5450 (office) | |||
| Media Relations | Investor Relations | |||
| Boston Scientific Corporation | Boston Scientific Corporation | |||
| [email protected] | [email protected] |
| BOSTON SCIENTIFIC CORPORATION CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) | ||
| Three Months Ended March 31, | ||
| in millions, except per share data | 2025 | 2024 |
| Net sales | $ 4,663 | $ 3,856 |
| Cost of products sold | 1,453 | 1,209 |
| Gross profit | 3,210 | 2,648 |
| Operating expenses: | ||
| Selling, general and administrative expenses | 1,597 | 1,364 |
| Research and development expenses | 443 | 366 |
| Royalty expense | 14 | 10 |
| Amortization expense | 219 | 214 |
| Contingent consideration net expense (benefit) | 5 | 17 |
| Restructuring net charges (credits) | 10 | 3 |
| 2,288 | 1,973 | |
| Operating income (loss) | 921 | 675 |
| Other income (expense): | ||
| Interest expense | (82) | (69) |
| Other, net | (34) | 2 |
| Income (loss) before income taxes | 805 | 608 |
| Income tax expense (benefit) | 133 | 115 |
| Net income (loss) | 672 | 493 |
| Net income (loss) attributable to noncontrolling interests | (2) | (1) |
| Net income (loss) attributable to Boston Scientific common stockholders | $ 674 | $ 495 |
| Net income (loss) per common share - basic | $ 0.46 | $ 0.34 |
| Net income (loss) per common share - diluted | $ 0.45 | $ 0.33 |
| Weighted-average shares outstanding | ||
| Basic | 1,477.2 | 1,468.4 |
| Diluted | 1,493.1 | 1,481.7 |
| Amounts may not add due to rounding. |
| BOSTON SCIENTIFIC CORPORATION NON-GAAP NET INCOME AND NET INCOME PER SHARE RECONCILIATIONS (Unaudited) | |||||||||
| Three Months Ended March 31, 2025 | |||||||||
| (in millions, except per share data) | Gross Profit | Operating Expenses | Operating Income (Loss) | Other Income (Expense) | Income (Loss) Before Income Taxes | Net Income (Loss) | Net Income (Loss) Attributable to Noncontrolling Interests | Net Income (Loss) Attributable to Boston Scientific Common Stockholders | Impact per Share |
| Reported | $ 3,210 | $ 2,288 | $ 921 | $ (116) | $ 805 | $ 672 | $ (2) | $ 674 | $ 0.45 |
| Non-GAAP adjustments: | |||||||||
| Amortization expense | — | (219) | 219 | — | 219 | 189 | 2 | 187 | 0.13 |
| Acquisition/divestiture-related net charges (credits) | 89 | (58) | 148 | 1 | 149 | 154 | — | 154 | 0.10 |
| Restructuring and restructuring-related net charges (credits) | 24 | (24) | 49 | — | 49 | 42 | — | 42 | 0.03 |
| Investment portfolio net losses (gains) and impairments | — | — | — | 8 | 8 | 7 | — | 7 | 0.00 |
| EU MDR implementation costs | 9 | (4) | 12 | — | 12 | 11 | — | 11 | 0.01 |
| Deferred tax expenses (benefits) | — | — | — | — | — | 47 | — | 47 | 0.03 |
| Adjusted | $ 3,332 | $ 1,982 | $ 1,350 | $ (106) | $ 1,243 | $ 1,121 | $ 0 | $ 1,121 | $ 0.75 |
| Three Months Ended March 31, 2024 | |||||||||
| (in millions, except per share data) | Gross Profit | Operating Expenses | Operating Income (Loss) | Other Income (Expense) | Income (Loss) Before Income Taxes | Net Income (Loss) | Net Income (Loss) Attributable to Noncontrolling Interests | Net Income (Loss) Attributable to Boston Scientific Common Stockholders | Impact per Share |
| Reported | $ 2,648 | $ 1,973 | $ 675 | $ (67) | $ 608 | $ 493 | $ (1) | $ 495 | $ 0.33 |
| Non-GAAP adjustments: | |||||||||
| Amortization expense | — | (214) | 214 | — | 214 | 184 | 2 | 182 | 0.12 |
| Acquisition/divestiture-related net charges (credits) | 10 | (54) | 64 | (0) | 64 | 77 | — | 77 | 0.05 |
| Restructuring and restructuring-related net charges (credits) | 25 | (21) | 46 | — | 46 | 40 | — | 40 | 0.03 |
| Investment portfolio net losses (gains) and impairments | — | — | — | (14) | (14) | (11) | — | (11) | (0.01) |
| EU MDR implementation costs | 9 | (5) | 14 | — | 14 | 12 | — | 12 | 0.01 |
| Deferred tax expenses (benefits) | — | — | — | — | — | 37 | — | 37 | 0.02 |
| Adjusted | $ 2,692 | $ 1,680 | $ 1,012 | $ (80) | $ 932 | $ 833 | $ 1 | $ 832 | $ 0.56 |
| An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document. | |||||||||
| Amounts may not add due to rounding. |
BOSTON SCIENTIFIC CORPORATION Q2 and FY 2025 GUIDANCE RECONCILIATIONS (Unaudited)
| Q2 2025 Estimate | Full Year 2025 Estimate | ||||
| (Low) | (High) | (Low) | (High) | ||
| Reported growth | 17.5 % | 19.5 % | 15.0 % | 17.0 % | |
| Impact of foreign currency fluctuations | 0.0 % | 0.0 % | 0.5 % | 0.5 % | |
| Operational growth | 17.5 % | 19.5 % | 15.5 % | 17.5 % | |
| Impact of certain acquisitions/divestitures | (4.5) % | (4.5) % | (3.5) % | (3.5) % | |
| Organic growth | 13.0 % | 15.0 % | 12.0 % | 14.0 % |
Earnings per Share
| Q2 2025 Estimate | Full Year 2025 Estimate | ||||
| (Low) | (High) | (Low) | (High) | ||
| GAAP results | $ 0.45 | $ 0.47 | $ 1.86 | $ 1.93 | |
| Amortization expense | 0.13 | 0.13 | 0.51 | 0.51 | |
| Acquisition/divestiture-related net charges (credits) | 0.05 | 0.05 | 0.22 | 0.22 | |
| Restructuring and restructuring-related net charges (credits) | 0.04 | 0.04 | 0.13 | 0.13 | |
| Other adjustments | 0.04 | 0.04 | 0.16 | 0.16 | |
| Adjusted results | $ 0.71 | $ 0.73 | $ 2.87 | $ 2.94 | |
| Amounts may not add due to rounding. |
Use of Non-GAAP Financial Measures
To supplement our unaudited consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share (EPS) that exclude certain charges (credits); operational net sales, which exclude the impact of foreign currency fluctuations; and organic net sales, which exclude the impact of foreign currency fluctuations as well as the impact of certain acquisitions and divestitures with less than a full period of comparable net sales. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.
To calculate adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share, we exclude certain charges (credits) from GAAP net income and GAAP net income attributable to Boston Scientific common stockholders, which include amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio net losses (gains) and impairments, restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits), EU MDR implementation costs, debt extinguishment net charges, deferred tax expenses (benefits) and certain discrete tax items. Amounts are presented after-tax using the company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate." Please refer to Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission or Part I, Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations in any Quarterly Report on Form 10-Q that we have filed or will file thereafter for an explanation of each of these adjustments and the reasons for excluding each item.
The GAAP financial measures most directly comparable to adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share are GAAP net income (loss), GAAP net income (loss) attributable to Boston Scientific common stockholders and GAAP net income (loss) per common share – diluted, respectively.
To calculate operational net sales growth rates, which exclude the impact of foreign currency fluctuations, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior periods. To calculate organic net sales growth rates, we also remove the impact of certain acquisitions and divestitures with less than a full period of comparable net sales. The GAAP financial measure most directly comparable to operational net sales and organic net sales is net sales reported on a GAAP basis.
Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the accompanying schedules.
SOURCE Boston Scientific Corporation